| News

T3 Pharma raises over 25 million Swiss francs

22.07.2020

T3 Pharmaceuticals AG has closed its third financing round, raising over 25 million Swiss francs. The Basel-based startup has developed a bacterial cancer therapy that it now intends to progress to clinical trials.

T3 Pharmaceuticals (T3 Pharma) has successfully closed a third financing round, raising over 25 million Swiss francs. According to a press release, the financing was co-led by existing investors, including the Boehringer Ingelheim Venture FundReference Capital SAWille Finance AG and private investors. The company has raised over 40 million francs since it was founded in 2015.

A spin-off from the Biozentrum of the University of Basel, T3 Pharma has developed a novel cancer therapy using live bacteria. According to the University of Basel, the idea behind its approach combines two natural phenomena: that bacteria can colonize tumors and that certain bacteria can inject self-made protein molecules into human cells.

T3 Pharma intends to use the new funds to test its therapy in clinical studies, and a clinical trial in patients with solid tumors is planned to start in early 2021. The first phase will focus on safety and tolerability of the lead candidate and identification of the optimal dosage.

“This significant financing round comes at a pivotal moment for our company as we leverage the full potential of our proprietary platform and enter the clinic with our lead candidate,” said Simon Ittig, co-founder and CEO of T3 Pharma.

T3 Pharma has received support from the BaseLaunch accelerator and incubator program, which is run by the investment and innovation promotion agency Basel Area Business & Innovation.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Holmusk opens new office in Basel
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Holmusk opens new office in Basel

Holmusk has opened an office in Basel. The company from Singapore develops digital therapies on the basis of data analysis....

Read More
Zifo RnD Solutions coming to Basel
Basel Area Business & Innovation, Innovation, Invest

Zifo RnD Solutions coming to Basel

Zifo RnD Solutions, a global provider of IT solutions for research-based organizations, opens its latest subsidiary in Basel. With Zifo...

Read More
Announcing the chosen ventures for the DayOne Accelerator (2020/2021)
Basel Area Business & Innovation, Innovation

Announcing the chosen ventures for the DayOne Accelerator (2020/2021)

The DayOne Accelerator ventures for 2020/21 have been chosen. Over 100 teams applied for the program which will run from...

Read More
«We will show the new product at the Olympic Games 2021 in Tokyo»
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

«We will show the new product at the Olympic Games 2021 in Tokyo»

The new Basel Area Business & Innovation Podcast offers exciting conversations with interesting interview partners. The first guest is surgeon...

Read More
Announcing the final winners of the i4Challenge 2020
Basel Area Business & Innovation, Innovation

Announcing the final winners of the i4Challenge 2020

The expert jury of the i4Challenge selected this year's winners. The solutions from the field of Industry 4.0 range from...

Read More
Patients stand to benefit from innovative tech project
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Patients stand to benefit from innovative tech project

The investment and innovation promotion agency Basel Area Business & Innovation is joining forces with several partners to realize a...

Read More
1 2 3 38

Do you have a question? We'd like to hear from you.